{"id":2359,"date":"2017-10-06T16:30:30","date_gmt":"2017-10-06T11:00:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2359"},"modified":"2025-05-12T14:30:53","modified_gmt":"2025-05-12T09:00:53","slug":"c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents","title":{"rendered":"C-X-C Chemokine Receptor Inhibitors\u2013The Emerging Therapeutic Agents"},"content":{"rendered":"<p><strong>C-X-C chemokine receptors (CXCR)<\/strong> is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily of 7-transmembrane domain receptors. Two types of chemokine receptors have been identified including monogamous chemokine receptors (bind to only one specific chemokine) and promiscuous chemokine receptors (bind to more than a dozen chemokines). A total of seven C-X-C chemokine receptors are known from <strong>CXCR1<\/strong> through to <strong>CXCR7<\/strong> out of which <strong>CXCR 1, 2 and 4 inhibitors<\/strong> being the key CXCR inhibitors are being developed as potential drugs.<\/p>\n<blockquote><p>The <strong>CXCR1 and 2<\/strong> mediates the <strong>GPCR signaling pathways<\/strong> and cellular functions such as calcium release, activation of <strong>Ras\/MAPK, PI3K signaling cascades<\/strong> as well as receptor internalization and chemotaxis. CXCR4 antagonist blocks the binding of its cognate ligand, stromal cell-derived factor 1 (SDF-1).<\/p><\/blockquote>\n<p>The CXCR inhibitors mainly target oncology based indications including acute myeloid leukemia, multiple myeloma, hematological malignancies, advanced solid tumors, and glioblastomamultiforme. Although chemokines and their receptors were originally identified as mediators of inflammatory diseases, however, it is being increasingly recognized that they serve as bridges between tumor cells and stromal cells. They also target respiratory, cardiovascular, metabolic, infectious and immune diseases.<\/p>\n<p>Currently, there is only one FDA approved CXCR inhibitor (type 4), <strong><em>Mozobil<\/em> (plerixafor)<\/strong> which received marketing approval in 2008 for Non-Hodgkin\u2019s Lymphoma and Multiple Myeloma. The pipeline activity in this area is robust with 20+ active pipeline products. Various companies including <strong>BioLineRx, Domp\u00e9Farmaceutici, and X4 Pharmaceuticals<\/strong> are developing therapeutic candidates in the late clinical stage (<strong>Phase III<\/strong>). Thus, the CXCR inhibitors development has emerged as a potential area of therapeutic research.<\/p>\n<p><strong><em>Ayushi Sinha<\/em><\/strong><\/p>\n<p><strong><em>Associate Analyst<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily of 7-transmembrane domain receptors. Two types of chemokine receptors have been identified including monogamous chemokine receptors (bind to only one specific chemokine) and promiscuous chemokine receptors (bind to more than a dozen chemokines). A [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2360,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1076,1070,1071,17581,204,17582,1077,1073,1072,1074,1075,1078],"industry":[17225],"therapeutic_areas":[17228,17234],"class_list":["post-2359","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biolinerx","tag-c-x-c-chemokine-receptors","tag-cxcr","tag-cxcr-inhibitor","tag-delveinsight","tag-dompe-farmaceutici","tag-dompefarmaceutici","tag-glioblastomamultiforme","tag-gpcr-signaling-pathways","tag-mozobil","tag-plerixafor","tag-x4-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>C-X-C Chemokine Receptor Inhibitors and Future Scope<\/title>\n<meta name=\"description\" content=\"C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C-X-C Chemokine Receptor Inhibitors and Future Scope\" \/>\n<meta property=\"og:description\" content=\"C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-10-06T11:00:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T09:00:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/10\/09021230\/Macrophage-detecting-cancer-cells.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"508\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C-X-C Chemokine Receptor Inhibitors and Future Scope","description":"C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents","og_locale":"en_US","og_type":"article","og_title":"C-X-C Chemokine Receptor Inhibitors and Future Scope","og_description":"C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily..","og_url":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-10-06T11:00:30+00:00","article_modified_time":"2025-05-12T09:00:53+00:00","og_image":[{"width":900,"height":508,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/10\/09021230\/Macrophage-detecting-cancer-cells.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents","url":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents","name":"C-X-C Chemokine Receptor Inhibitors and Future Scope","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/10\/09021230\/Macrophage-detecting-cancer-cells.jpg","datePublished":"2017-10-06T11:00:30+00:00","dateModified":"2025-05-12T09:00:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"C-X-C chemokine receptors (CXCR) is a family of G protein-coupled receptors that comprises of a large subfamily of the rhodopsin superfamily..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/c-x-c-chemokine-receptor-cxcr-inhibitors-emerging-therapeutic-agents#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/10\/09021230\/Macrophage-detecting-cancer-cells.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/10\/09021230\/Macrophage-detecting-cancer-cells.jpg","width":900,"height":508},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/10\/09021230\/Macrophage-detecting-cancer-cells-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioLineRx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">C-X-C chemokine receptors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CXCR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CXCR Inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dompe Farmaceutici<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Domp\u00e9Farmaceutici<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">glioblastomamultiforme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GPCR signaling pathways<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mozobil<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">plerixafor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">X4 Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BioLineRx<\/span>","<span class=\"advgb-post-tax-term\">C-X-C chemokine receptors<\/span>","<span class=\"advgb-post-tax-term\">CXCR<\/span>","<span class=\"advgb-post-tax-term\">CXCR Inhibitor<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Dompe Farmaceutici<\/span>","<span class=\"advgb-post-tax-term\">Domp\u00e9Farmaceutici<\/span>","<span class=\"advgb-post-tax-term\">glioblastomamultiforme<\/span>","<span class=\"advgb-post-tax-term\">GPCR signaling pathways<\/span>","<span class=\"advgb-post-tax-term\">Mozobil<\/span>","<span class=\"advgb-post-tax-term\">plerixafor<\/span>","<span class=\"advgb-post-tax-term\">X4 Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Oct 6, 2017","modified":"Updated on May 12, 2025"},"absolute_dates_time":{"created":"Posted on Oct 6, 2017 4:30 pm","modified":"Updated on May 12, 2025 2:30 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2359"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2359\/revisions"}],"predecessor-version":[{"id":32053,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2359\/revisions\/32053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2360"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2359"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2359"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}